
MeDevice Corp's Alternative To CTS Surgery: "Stretch it, don't cut it"

FOR IMMEDIATE RELEASE

MIAMI, Fla./EWorldWire/Aug. 27, 2003 --- MeDevice Corporation has developed a real solution for Carpal Tunnel Syndrome (CTS) that is low in cost, easily used by individuals and avoids surgery.

CTS is the number one reported medical problem, accounting for 50% of work related injuries and is considered the fastest growing form of workplace injury. CTS affects the quality of life of individuals and the economy by generating a serious loss in productivity and workdays that is estimated at billions of dollars every year for employers.

Surgery for CTS is the most common procedure in the U.S., and it accounts for \$1 Billion in direct medical costs annually. Once the decision is made to have surgery, the average loss of working days per CTS claim is 84, with an average workers compensation claim of over \$12,970. This has an enormous impact on the financial cost for the healthcare industry. In addition to surgery, common methods of dealing with CTS have traditionally included pharmacological (antiflamatories) and or movement restrictive braces.

Healthcare providers, CTS patients and those individuals wishing to avoid becoming victims of CTS have an option. MeDevice Corporation has developed a patented product called MDCtrack(TM) that will treat mild, moderate and severe forms of CTS. MDCtrack is a pneumatic traction device that has been clinically proven (in both patient experience and imagery) to stretch the ligament that surrounds the Median Nerve. In fact, the device is so simple to use that the device is recommended for those showing no signs of CTS but working or in some way participating in those activities that have a great deal of repetitive wrist action.

The founders / developers (Humberto Porrata, MD and Alejandro Porrata, MD, both specializing in Physical and Rehabilitation Medicine, along with Pain Management) recognized that the current treatment of CTS was outdated, too costly and not ultimately impacting the root cause of CTS, the Transverse Carpal Ligament.

MDCtrack is used for three short five-minute periods per day for four to six weeks as the initial treatment. It is used as needed (usually once per month) afterwards to maintain the ligament.

At a suggested price of \$100.00, the costs associated with treating CTR with physical therapy treatment and risky surgery will be significantly reduced. Because CTS is usually found in both wrists, MDCtrack was made to function on either left or right wrist, eliminating the need to buy two products.

MeDevice Corp's CEO Mario Porrara, projects that MDCtrack should be available for patient use by first quarter 2004. Mr. Porrata stated, "The company provides multiple wins - with over 850,000 new cases of CTS per year in the U.S., We are poised to grow fast, while providing the individual user of the device a non-invasive solution to the painful CTS."

For More Information on MeDevice Corp or MDCtrack Contact:

Dan Neufeld SVP
T: (469) 667- 6554
E: dneufeld@mindspring.com

HTML: <http://www.eworldwire.com/pressreleases/1635>

PDF: <http://www.eworldwire.com/pdf/1635.pdf>

ONLINE NEWSROOM: <http://www.eworldwire.com/newsroom/1678.htm>

LOGO: <http://www.eworldwire.com/newsroom/1678.htm>

CONTACT:

Dan Neufeld
MeDevice
PHONE. 469 667 6554
EMAIL: dneufeld@hci-na.com

KEYWORDS: Carpal Tunnel, Medical Device, Carpal Tunnel Surgery

SOURCE: MeDevice Corporation

AVAILABLE MEDIA: Photo: Photo media available (size: 0.0 k)
Book Cover
http://eworldwire.com//mediauploads/cover_200tall.gif